Back

Safety and tolerability of diuretics withdrawal in heart failure with reduced ejection fraction. The REDICAE trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 7 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jesus Alberto Torres Zamudio

Reina Sofia University Hospital, Cordoba (Spain)

4 More presentations in this session

Presentation thumbnail
Prognostic implications of adaptive and maladaptive right ventricular hypertrophy in patients with heart failure: a prospective observational cohort study
Doctor L. Dinc Asarcikli (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Predictors of early left ventricular reverse remodelling and prognosis in new-onset heart failure of non-ischemic origin
Doctor T. Hnat (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients
Doctor A. Ribeiro Teixeira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Cardiac reverse remodeling and SGLT2ii: insight from hemodynamic forces analysis
Doctor S. Prosperi (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial
thumbnail
Congress Presentation
Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.
thumbnail
Congress Presentation
Vericiguat in a real-world heart failure population: a single-centre experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources